Duexis FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 22, 2023.
FDA Approved: Yes (Discontinued) (First approved April 23, 2011)
Brand name: Duexis
Generic name: famotidine and ibuprofen
Dosage form: Tablets
Company: Horizon Pharma, Inc.
Treatment for: Osteoarthritis, Rheumatoid Arthritis, NSAID-Induced Ulcer Prophylaxis
Duexis (ibuprofen and famotidine) is an NSAID and histamine H2-receptor antagonist combination indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper GI ulcers.
- On August 17, 2023, the discontinuation of Duexis was posted on the FDA Drug Shortages page, noting that it was a business decision to discontinue the manufacture of the drug product.
Development timeline for Duexis
| Date | Article |
|---|---|
| Apr 25, 2011 | Approval Horizon Pharma Announces FDA Approval of Duexis (Ibuprofen/Famotidine) |
| May 26, 2010 | Horizon Pharma, Inc. Announces FDA Acceptance of Duexa New Drug Application for Filing |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
